论文部分内容阅读
目的低分子肝素钙联合依达拉奉,加用疏血通治疗进展性脑梗死临床疗效观察。方法治疗组62例应用低分子肝素钙联合依达拉奉治疗基础上加用疏血通,对照组应用低分子肝素钙联合依达拉奉治疗,治疗15d后,判断疗效。结果治疗组总有效率96.77%,对照组有效率87.10%,差异有统计学意义(P<0.05)。治疗组治疗后神经功能缺损评分减少明显大于对照组且有统计学意义。结论疏血通、低分子肝素钙联合依达拉奉治疗进展性脑梗死能有效控制进展。
Objective To observe the clinical efficacy of low molecular weight heparin combined with edaravone and Shuxuetong in the treatment of advanced cerebral infarction. Methods In the treatment group, 62 cases were treated with low molecular weight heparin calcium and edaravone plus Shuxuetong, while those in the control group were treated with low molecular weight heparin calcium and edaravone. After 15 days of treatment, the curative effect was judged. Results The total effective rate was 96.77% in the treatment group and 87.10% in the control group, the difference was statistically significant (P <0.05). After treatment, the neurological deficit scores of the treatment group decreased significantly than those of the control group and were statistically significant. Conclusion Shuxuetong, low molecular weight heparin combined with edaravone in patients with progressive cerebral infarction can effectively control the progress.